APA (7th ed.) Citation

Van De Laar CJ, Oude Voshaar MAH, Fakhouri WKH, Zaremba-Pechmann L, De Leonardis F, De La Torre I, & Van De Laar MAFJ. (2020). Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis. Dove Medical Press.

Chicago Style (17th ed.) Citation

Van De Laar CJ, Oude Voshaar MAH, Fakhouri WKH, Zaremba-Pechmann L, De Leonardis F, De La Torre I, and Van De Laar MAFJ. Cost-Effectiveness of a JAK1/JAK2 Inhibitor Vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis. Dove Medical Press, 2020.

MLA (9th ed.) Citation

Van De Laar CJ, et al. Cost-Effectiveness of a JAK1/JAK2 Inhibitor Vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis. Dove Medical Press, 2020.